The value of proteomic studies of the latest markers of kidney damage in the urine to assess the course, progression and complications in patients with CKD

Abstract

Сhronic kidney Disease (CKD) is the cause of both morbidity and mortality worldwide. In Ukraine, 12 % of the population is diagnosed with CKD. Significantly worsen the quality of life in patients with CKD progression of renal fibrosis and impaired mineral homeostasis. Early diagnosis and treatment are the main measures to prevent CKD progression and delay adverse effects. Deficiency of early, non-invasive biomarkers adversely affects the ability to rapidly detect and treat CKD. Proximal tubular lesions play an important role in the progression of CKD. There are new markers of kidney damage, such as uromodulin (UMOD), Klotho protein and post-translational modifications of fetuin A (FtA). Treatment of CKD in the early stages may improve renal function and/or slow the progression of CKD.